More evidence is needed on the additional efficacy of vedolizumab as a first-line biologic therapy for inflammatory bowel diseaseToshihiko Kakiuchi,Masato YoshiuraDIGESTIVE AND LIVER DISEASE（2023）引用 1|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
